Abstract
A mouse model of the neurodegenerative disease spinocerebellar ataxia type 1 reveals that changes in gene expression begin many weeks before the onset of symptoms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lin X., Antalffy, B., Kang, D., Orr, H. T. & Zoghbi, H. Y. Nat. Neurosci. 3, 157– 163 (2000).
Lunkes, A., Trottier, Y. & Mandel, J. L. Essays Biochem. 33, 149– 163 (1999).
Orr, H. T. et al. Nat. Genet. 4, 221–226 (1993).
Klement, I. A. et al. Cell 95, 41–53 (1998).
Schwarcz, R., Foster, A. C., French, E. D., Whetsell, W. O. Jr. & Kohler, C. Life Sci. 35, 19–32 (1984).
Greenamyre, J. T. Arch. Neurol. 43, 1058–1063 (1986).
diFiglia, M. Trends Neurosci. 13, 286–289 (1990).
Beal, M. F. Ann. Neurol. 38, 357–366 (1995).
Doble, A. Pharmacol. Ther. 81, 163–221 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nussbaum, R., Auburger, G. Neurodegeneration in the polyglutamine diseases: Act 1, Scene 1. Nat Neurosci 3, 103–104 (2000). https://doi.org/10.1038/72042
Issue Date:
DOI: https://doi.org/10.1038/72042
This article is cited by
-
Experimental therapeutics in transgenic mouse models of Huntington's disease
Nature Reviews Neuroscience (2004)